Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Allogeneic HSCT for Hematologic Malignancies
NCT01384513Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2011
- Primary completion
- Nov 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic hematopoietic stem cells in hematologic malignancy, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Aug 2011; status: completed.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT01384513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01384513.